A non-interventional, prospective study to evaluate change in physical activity, relationship satisfaction and psychological well-being in patients with rheumatoid arthritis after introduction of the JAK inhibitor filgotinib and also in their partners.

A non-interventional, prospective study to evaluate change in physical activity, relationship satisfaction and psychological well-being in patients with rheumatoid arthritis after introduction of the JAK inhibitor filgotinib and also in their partners. - Effect of JAK inhibition in RA on quality of life and partnership.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032128

Enrollment

Registered

2023-06-26

Start date

2023-08-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M06.8

Interventions

Group 1: 20 Patients (male/female, >18years) with RA will be started on Filgotinib, and their life-partners (no rheumatic disease, no treatment with DMARDs). Experimental group: 20 Filgotinib naïve R.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Experimental group: Filgotinib naive R.A., The patient is able to understand and give written, voluntary consent. Diagnosis of active RA and prescription of a new Filgotinib therapy by the treating rheumatologist. Partners: no rheumatic diseases, no treatment with DMARDs

Exclusion criteria

Exclusion criteria: Patient participates concurrently in another clinical trial. Known relevant heart, lung diseases or other medical contraindications that could influence the examination results. Patient is not able to participate due to any medical or psychological condition according to physician`s decision.

Design outcomes

Primary

Measure	Time frame
To show that treatment with Filgotinib restores physical participation in daily life in patients and in their partners as measured by a wrist accelerometer. The survey is conducted at 3 time points 1) before the start of treatment, 2) 12 and 3) 24 weeks after the start of therapy. Using a smartwatch, the number of steps is recorded over 7 consecutive days and thus the physical activity is measured.	—

Measure

Time frame

To show that treatment with Filgotinib restores physical participation in daily life in patients and in their partners as measured by a wrist accelerometer. The survey is conducted at 3 time points 1) before the start of treatment, 2) 12 and 3) 24 weeks after the start of therapy. Using a smartwatch, the number of steps is recorded over 7 consecutive days and thus the physical activity is measured.

—

Secondary

Measure	Time frame
To show that treatment with Filgotinib reduces perceived levels of pain in patients as well as improving relationship satisfaction and psychological well-being in patients and in their partners.	—

Countries

Germany

Contacts

Public ContactMandy Wernicke

Helios Fachklinik Vogelsang- Gommern

mandy.wernicke@helios-gesundheit.de+49 39200 67 143

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026